Chemotherapy remains the major standard of care for metastatic triple negative breast cancer (TNBC). However, TNBC often develops resistance to chemotherapy, which accelerates the formation of circulator tumor cells (CTCs) clusters. In this proposal, we aim to investigate the molecular mechanisms of chemotherapy resistance associated CTC cluster formation, and to develop new therapeutic approach to block CTC cluster formation and inhibit metastasis of breast cancer.

About Dr. Dashzeveg:
Nurmaa K. Dashzeveg, PhD, is a leading researcher in breast cancer metastasis, focusing on therapeutic approach to block breast cancer metastasis by investigating new modification of glycoproteins on circulating tumor cells. With a background in DNA damage response and tumor suppressor p53 from Tokyo Medical and Dental University and Tokyo Jikei University School of Medicine, her research aims to develop targeted treatments that selectively eliminate cancer cells.